Endocrinology, Vol 137, 2815-2822, Copyright © 1996 by Endocrine Society

ARTICLES

Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate

RM Solano, MJ Carmena, I Carrero, S Cavallaro, F Roman, C Hueso, S Travali, N Lopez-Fraile, LG Guijarro and JC Prieto
Department of Biochemistry and Molecular Biology, University of Alcala, Alcala de Henares, Spain.

Vasoactive intestinal peptide (VIP) is an important member of the group of neuropeptides that appears to be involved in the regulation of prostatic growth and function. Here we studied VIP receptors in membranes from human benign hyperplastic prostate. Accordingly to observations in rat prostatic membranes, [125I]VIP binding to human prostatic membranes suggested two classes of binding sites with high Kd = 0.22 nM) and low (Kd = 37.7 nM) affinities. VIP bound in human and rat membrane preparations to a common VIP/pituitary adenylate cyclase- activating peptide (PACAP) receptor, as VIP, PACAP-27, and PACAP-38 were equipotent for competition of [125I]VIP binding. A PACAP- preferring receptor appears to be expressed in human prostate, since [125I]PACAP binding was displaced with more potency by PACAP than by VIP, and a messenger RNA corresponding to type I PACAP receptor was found. Cross-linking experiments suggested a VIP receptor of about 71 kDa in human and 52 kDa in rat prostates. The binding of [125I]VIP to membranes and the labeling of the bands observed after electrophoresis were competitively inhibited by GTP, suggesting the coupling of VIP receptors to a G protein. Moreover, after solubilization and cross- linking, we observed a 120-kDa band that corresponded to the VIP receptor-alpha s association. VIP stimulated adenylyl cyclase activity in a dose-dependent manner, but the potency and/or the efficacy of VIP were lower in all human preparations studied than in rat prostatic membranes. In conclusion, this study clearly demonstrates the expression of VIP/PACAP common receptors associated with alpha s protein in human prostate and suggests that these neuropeptides could play an important and complex role in the physiology and pathophysiology of this human gland.

This article has been cited by other articles:

				C. MORETTI, C. MAMMI, G. V. FRAJESE, S. MARIANI, L. GNESSI, M. ARIZZI, F. WANNENES, and G. FRAJESE PACAP and Type I PACAP Receptors in Human Prostate Cancer Tissue Ann. N.Y. Acad. Sci., July 1, 2006; 1070(1): 440 - 449. [Abstract] [Full Text] [PDF]

				D. Farini, A. Puglianiello, C. Mammi, G. Siracusa, and C. Moretti Dual Effect of Pituitary Adenylate Cyclase Activating Polypeptide on Prostate Tumor LNCaP Cells: Short- and Long-Term Exposure Affect Proliferation and Neuroendocrine Differentiation Endocrinology, April 1, 2003; 144(4): 1631 - 1643. [Abstract] [Full Text] [PDF]

				M. D. Payet, L. Bilodeau, L. Breault, A. Fournier, L. Yon, H. Vaudry, and N. Gallo-Payet PAC1 Receptor Activation by PACAP-38 Mediates Ca2+ Release from a cAMP-dependent Pool in Human Fetal Adrenal Gland Chromaffin Cells J. Biol. Chem., January 10, 2003; 278(3): 1663 - 1670. [Abstract] [Full Text] [PDF]

				M. J. CARMENA, L. MONTALVO, R. M. SOLANO, C. CLEMENTE, I. D. ROMAN, M. SANCHEZ-CHAPADO, and J. C. PRIETO Effect of Flutamide Androgen-Receptor Blockade on Rat Prostatic VIP Receptor/Effector System Ann. N.Y. Acad. Sci., December 1, 2000; 921(1): 377 - 380. [Full Text] [PDF]

				Z. Rekasi, J. L. Varga, A. V. Schally, G. Halmos, P. Armatis, K. Groot, and T. Czompoly Antagonists of Growth Hormone-Releasing Hormone and Vasoactive Intestinal Peptide Inhibit Tumor Proliferation by Different Mechanisms: Evidence from in Vitro Studies on Human Prostatic and Pancreatic Cancers Endocrinology, June 1, 2000; 141(6): 2120 - 2128. [Abstract] [Full Text] [PDF]

				D. Vaudry, B. J. Gonzalez, M. Basille, L. Yon, A. Fournier, and H. Vaudry Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: From Structure to Functions Pharmacol. Rev., June 1, 2000; 52(2): 269 - 324. [Abstract] [Full Text] [PDF]

				H. Oka, L. Jin, E. Kulig, B. W. Scheithauer, and R. V. Lloyd Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Transforming Growth Factor-{beta}1-Induced Apoptosis in a Human Pituitary Adenoma Cell Line Am. J. Pathol., December 1, 1999; 155(6): 1893 - 1900. [Abstract] [Full Text] [PDF]

				R. Busto, I. Carrero, L. G. Guijarro, R. M. Solano, J. Zapatero, F. Noguerales, and J. C. Prieto Expression, pharmacological, and functional evidence for PACAP/VIP receptors in human lung Am J Physiol Lung Cell Mol Physiol, July 1, 1999; 277(1): L42 - L48. [Abstract] [Full Text] [PDF]

				J. Jongsma, M. H. Oomen, M. A. Noordzij, W. M. Van Weerden, G. J. M. Martens, T. H. van der Kwast, F. H. Schroder, and G. J. van Steenbrugge Kinetics of Neuroendocrine Differentiation in an Androgen-Dependent Human Prostate Xenograft Model Am. J. Pathol., February 1, 1999; 154(2): 543 - 551. [Abstract] [Full Text] [PDF]

				H. Oka, L. Jin, J. C. Reubi, X. Qian, B. W. Scheithauer, K. Fujii, T. Kameya, and R. V. Lloyd Pituitary Adenylate-Cyclase-Activating Polypeptide (PACAP) Binding Sites and PACAP/Vasoactive Intestinal Polypeptide Receptor Expression in Human Pituitary Adenomas Am. J. Pathol., December 1, 1998; 153(6): 1787 - 1796. [Abstract] [Full Text] [PDF]